September 8, 2025

**Medi-Cal Rx Updates**

**To reduce the number of individual faxes sent throughout the week, KHS is transitioning to a consolidated weekly bulletin for certain items.** Please find below the most recent Medi-Cal Rx updates. Please note, the links will take you directly to the Medi-Cal Rx website for full bulletin details.

|  |  |  |
| --- | --- | --- |
| **Medi-Cal Rx Bulletin** | **Description** | **Link** |
| Reminder: Prescription Supplements Are Not Covered | The Department of Health Care Services (DHCS) published a bulletin reminding supplements, even prescription versions are not covered. Claims may be considered for special groups on a case-by-case basis but would require prior authorization. | [Reminder: Prescription Supplements Are Not Covered](https://california.smartrx-test.lh.primetherapeutics.com/cms/medicalrx/static-assets/documents/provider/publications/2025.09_A_Reminder_Prescription_Supplements_Not_Covered.pdf) |
| Changes to the Medi-Cal Rx CCS Panel Authority Policy Coverage | The DHCS published a bulletin announcing a change to coverage of Sephience under the California Children’s Services (CCS). | [Changes to the Medi-Cal Rx CCS Panel Authority Policy Coverage](https://california.smartrx-test.lh.primetherapeutics.com/cms/medicalrx/static-assets/documents/provider/publications/2025.09_A_Changes_to_CCS_Panel_Authority_Formulary.pdf) |
| Maximum Allowable Ingredient Cost 30-Day Pharmacy Provider Notice | The DHCS published a bulletin informing of an upcoming change to the Maximum Allowable Ingredient Cost (MAIC) on October 1, 2025. | [Maximum Allowable Ingredient Cost 30-Day Pharmacy Provider Notice](https://california.smartrx-test.lh.primetherapeutics.com/cms/medicalrx/static-assets/documents/provider/publications/2025.09_A_MAIC_30-Day_Notice.pdf) |
| Coverage for Cell and Gene Therapy Access Model Medications | The DHCS published a bulletin describing a new program partnering with The Centers for Medicare & Medicaid Services’ (CMS) for coverage of Cell and Gene Therapy (CGT) to treat sickle cell disease. The drugs Lyfgenia and Casgevy will be carved out of the Medi-Cal Managed Care Plans and billed to the DHCS. Of note, they are not billed to MCRx as a pharmacy claim but billed as a medical benefit to the DHCS. | [Coverage for Cell and Gene Therapy Access Model Medications](https://california.smartrx-test.lh.primetherapeutics.com/cms/medicalrx/static-assets/documents/provider/publications/2025.09_A_Coverage_Cell_Gene_Therapy_Access_Model_Medications.pdf) |

[Provider Bulletins](https://www.kernfamilyhealthcare.com/providers/bulletins/) are available on the [KHS website](https://www.kernfamilyhealthcare.com/). Please visit the site regularly to stay informed about the latest updates and announcements.

If you have any additional questions, please contact your Provider Relations Representative at 1-800-391-2000, silent prompt option #5.

Sincerely,

Bruce Wearda, R.Ph.

Director of Pharmacy

Kern Health Systems